Early menopause

Early menopause, where standard hormone replacement therapy has failed, is another group of diseases where fetal precursor cell therapy has been used during the last 20 years with remarkable effectiveness.

Naturally the number of patients with early menopause (‘secondary amenorhea’) treated by fetal precursor cell transplantation cannot be compared with those in the usual ‘menopause’ among ~5 million of patients undergoing fetal precursor cell therapy during the last 80+ years.

Gynecologists have observed that for some reason ~50% of patients with early menopause do not respond well to the usual hormone replacement therapy with estrogen and progesterone, for reasons unknown.

The frequency of premature menopause has been increasing with such a speed in the ‘civilized’ world that U.S. gynecologists began to talk about a real ‘epidemic’. It is apparently due to the stress and pressures of high level jobs, requiring long hours, intense competition, hectic lifestyle, inadequate nutrition up to starvation, etc., that so many young women in their early thirties stop menstruating, and soon develop classical
symptoms of menopause and of its complications.

In not so rare instances it is due to the prolonged use of birth control pills. The high incidence of genital infections among the young people of our modern society plays an unspoken part.

Since 1995 we have made BCRO fetal precursor cell transplants available to physicians for treatment of their own patients. This was a result of 32+ years’ of research, GMP (‘Good Manufacturing Practice’) and clinical experience with fetal precursor cell transplantation in thousands of patients, including those described on this page.

Our own published studies document those patients with early menopause respond to fetal precursor cell transplantation unusually well.

The serum levels of hormones:

  • estrogen,
  • progesterone,
  • pituitary follicle-stimulating hormone (FSH),
  • pituitary luteinizing hormone (LH),
  • pituitary prolactine,
  • cortisol,
  • thyroid hormones,
  • pituitary thyroid-stimulating hormone (TSH),

All on menopausal levels before fetal precursor cell transplantation will start to return to normal after 4 weeks and remain at low / normal serum levels for 4 – 5 months after cell transplantation.

At that time they start to return to menopausal levels again, but they never reach their lowest levels before cell transplantation. Immediately after the next cell transplantation the level of all hormones goes back to nearly normal levels and will stay there for 6 – 7 months.

With each subsequent cell transplantation, the duration of clinical effect lasts longer. A judicious combination of fetal precursor cell transplantation with a hormone replacement therapy can bring these patient back to health. It has occurred frequently in the 80+ years history of cell transplantation, that it has been used in those patients where all known therapies had failed in helping the patient. Among those were patients with untreatable (‘intractable’) endometriosis.

Only those patients suffering of endometriosis understand how miserable this illness is, how the pain, and other symptoms, can drive one to suicide… particularly when no treatment gives any relief. Some such patients ‘at the end of the rope’ was treated by our BCRO fetal precursor cell transplants with very good results.

BCRO cell transplantation is not the treatment of choice for endometriosis; however it is an option to be used, when everything else fails.

Many western patients have undergone hysterectomy for uterine myomas because ‘the patient was of the age when it makes no difference’, etc., just to find out that their husbands left them because of the lack of uterus, or because they gained too much weight after the operation, etc. Patients with myomas of the uterus, in whom surgery was contraindicated, or who refused it, have been treated by fetal precursor cell transplantation. The size of uterine myomas was decreased by such therapy, and thus hysterectomy could have been avoided or postponed.